1. Our vision
  2. Santen explores the diverse needs of glaucoma patients at EGS 2022

Santen explores the diverse needs of glaucoma patients at EGS 2022

Wed 8 June 2022

01 June 2022 – Geneva, Switzerland – Santen EMEA is delighted to be taking part in the European Glaucoma Society’s (EGS) 15th congress in Athens, Greece from 4-8 June 2022. Santen aims to provide delegates with the knowledge, skills and motivation to enact real change to meet the diverse needs of patients and optimise the management of glaucoma. 

New perspectives in glaucoma care: Time for change?

Santen will host an international panel of glaucoma experts for New perspectives in glaucoma care: Time for change? – a promotional symposium on Tuesday 7 June, 12:30-14:00 UTC+3. 

Prof Norbert Pfeiffer (Germany) will facilitate discussions around the latest evidence on the role of the trabecular meshwork in aqueous humour flow and how resistance in this pathway is a major cause of intraocular pressure (IOP) elevation.1, the only modifiable risk factor for primary open angle glaucoma (POAG)2. Dr Anthony Khawaja (UK) will also share an overview of an expert consensus reached to guide surgeons across Europe as they navigate the latest innovations in surgical glaucoma management. 

“Conventional aqueous humour outflow through the trabecular meshwork accounts for the vast majority of flow. We now believe that resistance to aqueous outflow may result from dysfunction and degeneration in the trabecular meshwork,” said Prof Sheng Lim, UK. “Its role therefore remains an important focus of research and to better understand the development and progression of glaucoma.”

Changing the way glaucoma is understood and managed

For over a century, Santen has been committed to protecting the precious sense of sight. Glaucoma is growing in prevalence and is predicted to affect over seven million people in Europe by 2040.3 Currently a leading cause of blindness, the devastation of glaucoma related sight loss is preventable in 90% of cases.4

We want to change the way glaucoma is understood and managed, and so, in addition to the presentation of a number of scientific abstracts, Santen is hosting a range of interactive, educational initiatives at the booth (#EP2) at EGS 2022. Delegates will have the chance to engage with experts in a more intimate setting. Visit our booth at the congress to find out more. 

Santen in 10 is a new medical education gamified experience powered by real-life patient case studies that challenges ophthalmologists to maintain their learning in an engaging and unique format. Participation in the challenge takes only ten minutes and will be available online every month as well as live on the booth at EGS. 

We know that ophthalmologists work tirelessly to transform the lives of people with glaucoma and overcome the challenges faced in treating this chronic, progressive condition. Faced with issues around adherence, often caused by ocular surface disease (OSD),5 ophthalmologists work with medical treatment options that have stayed broadly the same for the last 25 years.4

We’re not afraid to challenge the status quo in glaucoma management. In pursuit of better eye health for all, our long-term mission is to build a portfolio that supports ophthalmologists in meeting the diverse needs of their patient population and address these challenges.

References

  1. Buffault J, et al; The trabecular meshwork: Structure, function and clinical implications. A review of the literature; J Fr Ophtalmol (2020) 43(7):e217-e230 
  2. Anderson A; Exercise and glaucoma: positive steps toward finding another modifiable risk factor to prevent vision loss; Ophthal (2019) 126(7):965- 966
  3. Tham Y-C, et al. Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040: A Systematic Review and Meta-Analysis 2014;121:2081–90.
  4. Glaucoma Research Foundaton. ‚Glaucoma Facts and Stats‘. Available at: https://glaucoma.org/glaucoma-facts-and-stats/ . Accessed May 2022 
  5. Kaštelan S, Tomić M, Metež Soldo K, Salopek-Rabatić J. How ocular surface disease impacts the glaucoma treatment outcome. Biomed Res Int. 2013;2013:696328. doi:10.1155/2013/696328

NP-GLAU-EMEA-0278
Date of preparation: May 2022